FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
SAGE-547 Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in SRSE
Conference Call Scheduled Today at 8:30 a.m. ET
CAMBRIDGE, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today reported business highlights and financial results for the first quarter ended March 31, 2015.
"This year has been transformational for SAGE. We continue to advance the development of our new medicines for CNS disorders where there are... More
SAGE-547 Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in SRSE
Conference Call Scheduled Today at 8:30 a.m. ET
CAMBRIDGE, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today reported business highlights and financial results for the first quarter ended March 31, 2015.
"This year has been transformational for SAGE. We continue to advance the development of our new medicines for CNS disorders where there are... More
SAGE-547 Demonstrates Favorable Tolerability
Pharmacodynamic Activity Corroborated by Continuous EEG Findings
Phase 3 STATUS Trial Expected to Initiate by Mid-2015
Conference Call Scheduled Today at 8:30 a.m. ET
CAMBRIDGE, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq: SAGE) today announced that SAGE-547 demonstrated robust activity, with a 77 percent response rate in evaluable patients with super-refractory status epilepticus (SRSE), in a successfully completed Phase 1/2 clinical trial. SAGE-547 also demonstrated favorable tolerability and a benefit-risk profile... More
SAGE-547 Demonstrates Favorable Tolerability
Pharmacodynamic Activity Corroborated by Continuous EEG Findings
Phase 3 STATUS Trial Expected to Initiate by Mid-2015
Conference Call Scheduled Today at 8:30 a.m. ET
CAMBRIDGE, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq: SAGE) today announced that SAGE-547 demonstrated robust activity, with a 77 percent response rate in evaluable patients with super-refractory status epilepticus (SRSE), in a successfully completed Phase 1/2 clinical trial. SAGE-547 also demonstrated favorable tolerability and a benefit-risk profile... More
